Skip to main content

Table 1 Baseline demographic and clinical characteristics of the samples

From: Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217

Cohort 1 Overall Control MCI-AD (Aβ+) p    
n 52 27 25     
 Age 72.13 (5.54) 72.63 (5.38) 71.60 (5.77) 0.509    
 Sex, female 25 (48.1) 10 (37.0) 15 (60.0) 0.168    
 APOEϵ4 positive 25 (48.1) 6 (22.2) 19 (76.0) < 0.001    
 Education 11.40 (2.97) 11.63 (2.44) 11.16 (3.48) 0.573    
 Plasma p-tau217+Janssen, pg/ml 0.05 (0.04) 0.03 (0.01) 0.08 (0.05) < 0.001    
 Plasma p-tau217Lilly, pg/ml 0.43 (0.21) 0.31 (0.05) 0.56 (0.23) < 0.001    
Cohort 2 Overall MCI-AD (Aβ+) MCI-other Aβ− MCI-other Aβ+ Stable MCI Aβ− Stable MCI Aβ+ p across the groups
n 147 45 24 9 51 18  
 Age 72.06 (7.71) 75.89 (6.97) 73.12 (7.60) 71.67 (5.36) 68.84 (7.70) 70.39 (6.70) < 0.001
 Sex, female 86 (58.5) 34 (75.6) 11 (45.8) 3 (33.3) 29 (56.9) 9 (50.0) 0.042
 APOEϵ4 positive 82 (55.8) 36 (80.0) 11 (45.8) 7 (77.8) 14 (27.5) 14 (77.8) < 0.001
 MMSE 27.37 (1.78) 26.09 (1.65) 27.00 (1.82) 27.67 (2.06) 28.45 (1.05) 27.83 (1.47) < 0.001
 Total follow-up, years 4.92 (2.09) 3.66 (1.63) 3.90 (1.97) 4.49 (2.00) 6.34 (1.70) 5.64 (1.65) < 0.001
 Plasma p-tau217+Janssen, pg/ml 0.08 (0.07) 0.13 (0.08) 0.05 (0.04) 0.09 (0.07) 0.04 (0.03) 0.07 (0.04) < 0.001
 Plasma p-tau217Lilly, pg/ml 0.30 (0.18) 0.46 (0.18) 0.23 (0.11) 0.30 (0.15) 0.20 (0.12) 0.31 (0.11) < 0.001
 CSF p-tau217+Janssen, pg/ml 11.66 (16.29) 25.29 (23.38) 4.72 (3.75) 6.61 (3.52) 3.58 (2.38) 12.27 (7.22) < 0.001
 CSF p-tau217Lilly, pg/ml 17.83 (22.92) 38.28 (30.62) 8.03 (6.96) 10.02 (4.49) 5.09 (3.26) 19.80 (14.60) < 0.001
  1. Values displayed are mean (SD) for continuous variables and n (%) for categorical variables. Pairwise differences between the groups are displayed in Additional file 1: Table S2
  2. amyloid-β, MMSE Mini-Mental State Examination, MCI mild cognitive impairment, p-tau phosphorylated tau